Company intelligence / Profile preview

Fervent Pharmaceuticals

Greenville, North Carolina, United Statesferventpharma.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 2

Overview

FP-101 is currently in Phase 2 clinical trials as a non-hormonal, non-herbal, non-antidepressant treatment for vasomotor symptoms associated with menopause. The company is conducting a randomized, double-blind, placebo-controlled clinical trial designed as a fully decentralized clinical trial (DCT) to evaluate FP-101 versus placebo in peri- and post-menopausal women[10].

Therapeutic areas: Women's HealthEndocrinology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

FP-101

Partnerships

IQVIA (clinical trial sponsor)[5]

Beyond the preview

Go deeper on Fervent Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fervent Pharmaceuticals.

Explore the full profile